Streetbeat News

ALLR

Allarity Therapeutics, Inc.

https://www.allarity.com

Industry

Biotechnology

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Open

1.40

Mkt cap

1.9M

Volume

365K

High

1.40

P/E Ratio

-0.13

52-wk high

666.00

Low

1.27

Div yield

N/A

52-wk low

1.26

Allarity Therapeutics (NASDAQ:ALLR) reported a fiscal year net loss of $11.9 million, an improvement from the previous year's net loss of $16.1 million. The company's quarterly losses per share were $(10.26), which represents a 99.67% increase over the previous year's losses of $(3.09 thousand) per share.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 12:21 pm

Allarity Therapeutics received a notice from Novartis on Jan 26 to terminate their agreement on Dovitinib due to a material breach for lack of financial payment, as disclosed in an 8-K filing.

Portfolio Pulse from Charles Gross

February 01, 2024 | 9:52 pm

In Thursday's after-market session, several healthcare stocks experienced significant movements. Virpax Pharmaceuticals (VRPX) saw an 18.7% increase, while Aadi Bioscience (AADI) suffered a 59.8% decrease. Other notable gainers include Heart Test Laboratories (HSCS), Delcath Systems (DCTH), Allarity Therapeutics (ALLR), Palisade Bio (PALI), and Dermata Therapeutics (DRMA). On the losing side, Aileron Therapeutics (ALRN), Ontrak (OTRK), Acurx Pharmaceuticals (ACXP), Telesis Bio (TBIO), and RenovoRx (RNXT) saw declines ranging from 7.45% to 16.58%.

Portfolio Pulse from Benzinga Insights

December 14, 2023 | 9:31 pm

Allarity Therapeutics announced the termination of James Cullem as CEO and the appointment of Thomas Jensen as the new CEO on December 8, 2023.

Portfolio Pulse from Charles Gross

December 11, 2023 | 11:33 am

During Friday's intraday session, several healthcare stocks experienced significant movements. Intensity Therapeutics (INTS) saw a notable increase of 107.2%, while Conduit Pharmaceuticals (CDT) and ALX Oncology Holdings (ALXO) also saw substantial gains. On the other hand, AquaBounty Techs (AQB), Veradigm (MDRX), and Cano Health (CANO) were among the stocks that declined. These movements reflect the dynamic nature of the healthcare sector and may be influenced by company-specific news or broader market trends.

Portfolio Pulse from Benzinga Insights

December 08, 2023 | 5:31 pm

AeroVironment, Inc. (NASDAQ:AVAV) shares fell over 9% despite reporting Q2 earnings and revenue that beat estimates. The company's adjusted earnings were 97 cents per share, surpassing the expected 62 cents, with revenue at $180.8 million against the forecasted $170.908 million. Other stocks experienced significant movements in Wednesday's mid-day session, with notable gainers including Sera Prognostics, Inc. (NASDAQ:SERA) and MicroAlgo Inc. (NASDAQ:MLGO), and losers such as NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) and ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA).

Portfolio Pulse from Lisa Levin

December 06, 2023 | 7:43 pm

Health care stocks experienced significant movement in Wednesday's intraday session. Sera Prognostics (SERA) saw a massive increase of 231.9%, while OptiNose (OPTN) led the decliners with a 22.4% drop. Other notable gainers include Phio Pharma (PHIO), Syros Pharmaceuticals (SYRS), Altimmune (ALT), Arvinas (ARVN), and Altamira Therapeutics (CYTO). On the losing side were Mira Pharmaceuticals (MIRA), InVivo Therapeutics Hldg (NVIV), Allarity Therapeutics (ALLR), GlucoTrack (GCTK), and Sonoma Pharmaceuticals (SNOA).

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:31 pm

SentinelOne, Inc. (NYSE:S) shares surged over 18% in pre-market trading following the release of their Q3 results, which exceeded analyst expectations. The company reported $164.2 million in revenue, surpassing the $156.09 million estimate, and an adjusted loss of 3 cents per share, better than the expected 8 cents per share loss. SentinelOne also increased its full-year 2024 revenue forecast from $605 million to $616 million.

Portfolio Pulse from Lisa Levin

December 06, 2023 | 1:32 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Phio Pharma (PHIO) led the gainers with a 33.9% increase, while OptiNose (OPTN) saw the largest decline among the losers, dropping 16.3%. The changes in stock prices are reflective of market reactions to company-specific news or broader sector shifts.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 1:06 pm

In Tuesday's after-market session, several healthcare stocks experienced significant movements. Phio Pharma (PHIO) saw a 19.6% increase, while Lucy Scientific Discovery (LSDI) rose by 9.34%. Aclaris Therapeutics (ACRS) went up by 8.47%, and Minerva Surgical (UTRS) by 8.36%. Pasithea Therapeutics (KTTA) and Phreesia (PHR) also saw gains of 6.77% and 5.76%, respectively. On the downside, Allarity Therapeutics (ALLR) dropped by 8.1%, InVivo Therapeutics (NVIV) by 7.06%, Longeveron (LGVN) by 6.2%, Surrozen (SRZN) by 6.01%, Impel Pharmaceuticals (IMPL) by 5.58%, and BioCardia (BCDA) by 5.49%.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.